DENVER and CHICAGO, February 21, 2023 – TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”), an oncology company in the process of going public through a business combination transaction (the “Business Combination”) with MedTech Acquisition Corporation (Nasdaq: MTAC) (“MedTech” or “MTAC”),
Data Further Supports the Potential of the Company’s Therapeutic Platform to Improve Immunotherapy Outcomes for Patients with Liver and Pancreatic Tumors DENVER and CHICAGO, February 16, 2023 – TriSalus Life Sciences®, Inc. (“TriSalus” or the “Company”), an oncology company in the process of going